0000000000603704

AUTHOR

F Cardillo

showing 2 related works from this author

Measurement of the Lund jet plane using charged particles in 13 TeV proton-proton collisions with the ATLAS detector

2020

The prevalence of hadronic jets at the LHC requires that a deep understanding of jet formation and structure is achieved in order to reach the highest levels of experimental and theoretical precision. There have been many measurements of jet substructure at the LHC and previous colliders, but the targeted observables mix physical effects from various origins. Based on a recent proposal to factorize physical effects, this Letter presents a double-differential cross-section measurement of the Lund jet plane using 139  fb−1 of √s=13  TeV proton-proton collision data collected with the ATLAS detector using jets with transverse momentum above 675 GeV. The measurement uses charged particles to ac…

:Kjerne- og elementærpartikkelfysikk: 431 [VDP]Protonshowers [parton]13000 GeV-cmsPhysics::Instrumentation and DetectorsHadronGeneral Physics and Astronomyjet: transverse momentumPhysical Effects01 natural sciencestransverse momentum [jet]High Energy Physics - ExperimentSubatomär fysikHigh Energy Physics - Experiment (hep-ex)Charged ParticlesSubatomic PhysicsComputingMilieux_COMPUTERSANDEDUCATIONscattering [p p][PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Parton showerNuclear ExperimentGeneralLiterature_REFERENCE(e.g.dictionariesencyclopediasglossaries)PhysicsSettore FIS/01Jet (fluid)Large Hadron ColliderDouble Differential Cross SectionsDetectorhadronic [jet]Monte Carlo [numerical calculations]ATLASTransverse Momentacharged particleCharged particlemedicine.anatomical_structureCERN LHC Coll:Nuclear and elementary particle physics: 431 [VDP]colliding beams [p p]numerical calculations: Monte CarloParticle Physics - Experimentp p: scatteringCiências Naturais::Ciências Físicas530 Physicsformation [jet]Astrophysics::High Energy Astrophysical Phenomena:Ciências Físicas [Ciências Naturais]FOS: Physical sciencesMeasurements ofLHC ATLAS High Energy Physicsjet: formation530GeneralLiterature_MISCELLANEOUSMonte Carlo Modelparton: showersNuclear physicsdifferential cross section: measuredAtlas (anatomy)Fragmentationmeasured [differential cross section]0103 physical sciencesmedicineddc:530High Energy Physicsstructure010306 general physicsATLAS CollaborationScience & Technology010308 nuclear & particles physicsComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKSFísicajet: hadronic530 Physikangular resolutionProton Proton CollisionsElementary Particles and FieldsHigh Energy Physics::ExperimentDetector EffectsHadron-hadron collisionsp p: colliding beamsMathematicsofComputing_DISCRETEMATHEMATICSacceptanceexperimental results
researchProduct

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HE…

2020

We analyzed data from 738 HER2‐positive metastatic breast cancer (mbc) patients treated with pertuzumab‐based regimens and/or T‐DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by immunohistochemistry (IHC). The median progression‐free survival at first‐line (mPFS1) was 12 months. Pertuzumab as first‐line conferred longer mPFS1 compared to other first‐line treatments (16 vs. 9 months, p = 0.0001), regardless of IHC subtype. Median PFS in second‐line (mPFS2) was 7 months, with no difference by IHC subtype, but it was more favorable with T‐DM1 compared to other agents (7 vs. 6 months, p = 0.03). There was no PFS2 gain in patients with tumors expressing b…

OncologyCancer ResearchMultivariate analysisSettore MED/06 - Oncologia MedicaReceptor ErbB-2T-DM1Estrogen receptor0302 clinical medicineErbB-2TrastuzumabReceptorsAntineoplastic Combined Chemotherapy Protocols80 and overMolecular Targeted TherapyNeoplasm MetastasisCancer Therapy and PreventionProgesteroneAged 80 and overadvanced breast cancerTumorreal worldMiddle AgedPrognosisMetastatic breast cancerImmunohistochemistryGene Expression Regulation NeoplastictrastuzumabOncologyReceptors Estrogen030220 oncology & carcinogenesisImmunohistochemistryFemaleadvanced breast cancer; HER2 positive; pertuzumab; real world; T-DM1; trastuzumab; Adult; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers Tumor; Breast Neoplasms; Female; Humans; Immunohistochemistry; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Receptor ErbB-2; Receptors Estrogen; Receptors Progesterone; Gene Expression Regulation NeoplasticPertuzumabReceptors ProgesteroneHER2 positive; T-DM1; advanced breast cancer; pertuzumab; real world; trastuzumabmedicine.drugReceptorAdultHER2 positivemedicine.medical_specialtyT‐DM1advanced breast cancer; HER2 positive; pertuzumab; real world; T-DM1; trastuzumab; chemotherapyBreast Neoplasms03 medical and health sciencesBreast cancerSettore MED/04 - PATOLOGIA GENERALEpertuzumabInternal medicinemedicineBiomarkers TumorHumansAgedNeoplasm StagingNeoplasticbusiness.industrymedicine.diseaseEstrogenSettore CHIM/08 - Chimica FarmaceuticaGene Expression RegulationMED/06 - ONCOLOGIA MEDICAbusinessBiomarkersHormone
researchProduct